Septerna (NASDAQ:SEPN) Trading Up 6.7% – What’s Next?

Septerna, Inc. (NASDAQ:SEPN)’s stock price traded up 6.7% on Wednesday . The company traded as high as $23.10 and last traded at $23.1540. 99,459 shares traded hands during trading, a decline of 83% from the average session volume of 573,105 shares. The stock had previously closed at $21.69.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Wells Fargo & Company raised shares of Septerna from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $18.00 to $28.00 in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Septerna in a research report on Friday, September 5th. HC Wainwright raised their price target on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Finally, Wall Street Zen upgraded Septerna from a “sell” rating to a “buy” rating in a research note on Sunday. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Septerna Stock Performance

The firm has a market capitalization of $1.05 billion and a P/E ratio of -15.35. The business has a fifty day moving average of $19.61 and a 200-day moving average of $14.06.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The business had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. On average, equities research analysts forecast that Septerna, Inc. will post -7.11 earnings per share for the current fiscal year.

Insider Buying and Selling at Septerna

In related news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president owned 92,911 shares of the company’s stock, valued at $1,677,972.66. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Russell Investments Group Ltd. acquired a new stake in shares of Septerna in the 3rd quarter worth approximately $36,000. Covestor Ltd raised its holdings in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after purchasing an additional 1,296 shares in the last quarter. BNP Paribas Financial Markets lifted its position in Septerna by 88.0% in the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock worth $78,000 after purchasing an additional 1,945 shares during the period. KLP Kapitalforvaltning AS bought a new position in Septerna during the 1st quarter valued at $49,000. Finally, JPMorgan Chase & Co. boosted its stake in Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.